Eli Lilly price target raised to $1,101 from $1,001 at BMO Capital
The Fly

Eli Lilly price target raised to $1,101 from $1,001 at BMO Capital

BMO Capital raised the firm’s price target on Eli Lilly to $1,101 from $1,001 and keeps an Outperform rating on the shares. The firm cites the company’s Q2 earnings beat and the “exceptional execution” on the largest BioPharma manufacturing expansion since the pandemic, the analyst tells investors in a research note. Commercial excellence and nimbleness in the U.S. market is becoing the expectations from Lilly after its two healthy guidance raises in a row, BMO added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App